News

IRADIMED CORPORATION to Hold 2024 Third Quarter Financial Results Conference Call on October 31st

WINTER SPRINGS, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release…

1 month ago

TELA Bio Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

MALVERN, Pa., Oct. 24, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing…

1 month ago

ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2025

Year-over-year revenue grows 11%, operating profit up 34%, non-GAAP operating profit up 27%Operating cash flow of $326 million Note: A webcast of…

1 month ago

Ardelyx Shares Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week

WALTHAM, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to…

1 month ago

Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024

HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents…

1 month ago

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

Strengthens Lyell’s clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT’s multi-center Phase…

1 month ago

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination

Data from Animal Model Study Demonstrate XPro™ converts microglia from a demyelinating cell to a remyelinating cell Multi-year study published…

1 month ago

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

WORCESTER, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical…

1 month ago

Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701

- INZ-701 was well-tolerated and significantly increased plasma pyrophosphate (PPi) levels in patients with end-stage kidney disease (ESKD) undergoing hemodialysis;…

1 month ago

Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION24 OCTOBER 2024 at 19.50 EEST         Inside information: Orion terminates ODM-111 development program…

1 month ago